Magdalena Gorska
Concepts (359)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 23 | 2026 | 1919 | 2.310 |
Why?
| | Estradiol | 6 | 2016 | 523 | 2.180 |
Why?
| | Th2 Cells | 9 | 2024 | 177 | 2.170 |
Why?
| | Osteosarcoma | 5 | 2016 | 73 | 1.850 |
Why?
| | Vehicle Emissions | 3 | 2020 | 65 | 1.560 |
Why?
| | Nitric Oxide Synthase Type I | 3 | 2015 | 29 | 1.360 |
Why?
| | Adaptor Proteins, Signal Transducing | 8 | 2012 | 439 | 1.350 |
Why?
| | Killer Cells, Natural | 4 | 2020 | 467 | 1.280 |
Why?
| | Maternal Exposure | 4 | 2020 | 201 | 1.230 |
Why?
| | Lymphocytes | 7 | 2026 | 394 | 0.970 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 4 | 2021 | 21 | 0.950 |
Why?
| | Hypersensitivity | 2 | 2024 | 260 | 0.860 |
Why?
| | Bone Neoplasms | 3 | 2016 | 249 | 0.840 |
Why?
| | Interleukin-17 | 4 | 2020 | 119 | 0.790 |
Why?
| | Lactams, Macrocyclic | 2 | 2013 | 50 | 0.770 |
Why?
| | Benzoquinones | 2 | 2013 | 48 | 0.760 |
Why?
| | Signal Transduction | 15 | 2026 | 5153 | 0.680 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2163 | 0.660 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2020 | 656 | 0.660 |
Why?
| | Allergens | 7 | 2025 | 400 | 0.650 |
Why?
| | Granzymes | 1 | 2020 | 50 | 0.650 |
Why?
| | Mutation, Missense | 2 | 2012 | 340 | 0.640 |
Why?
| | Oxidative Stress | 6 | 2016 | 1327 | 0.600 |
Why?
| | Mice | 26 | 2026 | 18092 | 0.580 |
Why?
| | Chaperonin 60 | 2 | 2016 | 13 | 0.540 |
Why?
| | Bronchial Hyperreactivity | 5 | 2015 | 104 | 0.530 |
Why?
| | Protein Tyrosine Phosphatases | 5 | 2016 | 169 | 0.530 |
Why?
| | Heat-Shock Proteins | 2 | 2016 | 141 | 0.510 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2016 | 133 | 0.500 |
Why?
| | Estrogen Antagonists | 1 | 2016 | 45 | 0.490 |
Why?
| | Estrogen Receptor beta | 1 | 2016 | 43 | 0.480 |
Why?
| | Apoptosis | 6 | 2016 | 2575 | 0.480 |
Why?
| | DNA Breaks | 1 | 2015 | 3 | 0.470 |
Why?
| | Animals | 31 | 2026 | 37642 | 0.470 |
Why?
| | Interleukin-1beta | 1 | 2017 | 386 | 0.460 |
Why?
| | Bacterial Outer Membrane Proteins | 4 | 2016 | 62 | 0.460 |
Why?
| | Mitochondrial Proteins | 2 | 2016 | 260 | 0.450 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 170 | 0.450 |
Why?
| | Neuroblastoma | 1 | 2016 | 162 | 0.440 |
Why?
| | Intracellular Signaling Peptides and Proteins | 6 | 2021 | 467 | 0.440 |
Why?
| | Cytokines | 8 | 2026 | 2093 | 0.430 |
Why?
| | Virus Diseases | 1 | 2017 | 215 | 0.430 |
Why?
| | Protein Processing, Post-Translational | 5 | 2016 | 463 | 0.430 |
Why?
| | Cell Line, Tumor | 8 | 2016 | 3504 | 0.420 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2011 | 719 | 0.420 |
Why?
| | Leukocyte Common Antigens | 4 | 2015 | 90 | 0.410 |
Why?
| | Neurodegenerative Diseases | 1 | 2016 | 140 | 0.410 |
Why?
| | Cell Survival | 8 | 2016 | 1131 | 0.390 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 435 | 0.390 |
Why?
| | Hippocampus | 2 | 2015 | 939 | 0.380 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2021 | 1113 | 0.380 |
Why?
| | Immunity, Innate | 5 | 2024 | 852 | 0.380 |
Why?
| | Lymphopenia | 1 | 2012 | 67 | 0.380 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2012 | 47 | 0.370 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2011 | 7 | 0.370 |
Why?
| | Inflammation | 2 | 2017 | 2895 | 0.350 |
Why?
| | Lymphocyte Activation | 6 | 2021 | 1142 | 0.350 |
Why?
| | Cell Proliferation | 9 | 2021 | 2504 | 0.350 |
Why?
| | Disease Models, Animal | 8 | 2022 | 4413 | 0.340 |
Why?
| | Neoplasms | 2 | 2016 | 2731 | 0.330 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2016 | 195 | 0.320 |
Why?
| | Humans | 48 | 2026 | 141267 | 0.310 |
Why?
| | rab GTP-Binding Proteins | 2 | 2010 | 78 | 0.310 |
Why?
| | Immunological Synapses | 1 | 2009 | 17 | 0.310 |
Why?
| | Interleukin-13 | 3 | 2020 | 149 | 0.310 |
Why?
| | Membrane Proteins | 3 | 2025 | 1157 | 0.300 |
Why?
| | Cell Differentiation | 4 | 2020 | 2001 | 0.300 |
Why?
| | Ovalbumin | 3 | 2022 | 196 | 0.300 |
Why?
| | Hydrogen Peroxide | 4 | 2015 | 339 | 0.290 |
Why?
| | Air Pollutants | 1 | 2013 | 429 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 5 | 2021 | 150 | 0.280 |
Why?
| | Mice, Knockout | 7 | 2025 | 3065 | 0.260 |
Why?
| | Interleukin-5 | 2 | 2008 | 42 | 0.260 |
Why?
| | Transcription, Genetic | 3 | 2026 | 1493 | 0.260 |
Why?
| | Capillary Permeability | 1 | 2007 | 148 | 0.250 |
Why?
| | Dynamin II | 1 | 2006 | 4 | 0.250 |
Why?
| | Mice, Inbred BALB C | 5 | 2022 | 1271 | 0.250 |
Why?
| | Aurintricarboxylic Acid | 2 | 2016 | 4 | 0.250 |
Why?
| | Bronchoalveolar Lavage | 2 | 2018 | 92 | 0.240 |
Why?
| | MAP Kinase Signaling System | 5 | 2026 | 324 | 0.240 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 2 | 2015 | 10 | 0.240 |
Why?
| | Gene Expression Regulation | 5 | 2026 | 2608 | 0.240 |
Why?
| | Respiratory Tract Diseases | 1 | 2007 | 180 | 0.230 |
Why?
| | Neutrophils | 2 | 2025 | 1283 | 0.230 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2026 | 53 | 0.230 |
Why?
| | Immunoglobulin E | 3 | 2018 | 331 | 0.230 |
Why?
| | Cytosol | 1 | 2026 | 229 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 2061 | 0.220 |
Why?
| | T-Lymphocytes | 4 | 2009 | 2006 | 0.220 |
Why?
| | Th17 Cells | 2 | 2016 | 107 | 0.220 |
Why?
| | Transforming Growth Factor beta | 4 | 2012 | 498 | 0.210 |
Why?
| | Cell Death | 2 | 2016 | 388 | 0.210 |
Why?
| | Disease Susceptibility | 2 | 2017 | 352 | 0.210 |
Why?
| | Jurkat Cells | 5 | 2015 | 138 | 0.210 |
Why?
| | Cells, Cultured | 7 | 2020 | 4205 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 1241 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2022 | 649 | 0.200 |
Why?
| | NF-kappa B | 1 | 2007 | 690 | 0.200 |
Why?
| | Mice, Inbred C57BL | 7 | 2021 | 5901 | 0.200 |
Why?
| | Mast Cells | 1 | 2024 | 153 | 0.200 |
Why?
| | Catalytic Domain | 4 | 2016 | 223 | 0.190 |
Why?
| | Molecular Docking Simulation | 4 | 2016 | 111 | 0.180 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2012 | 75 | 0.180 |
Why?
| | Immune System | 1 | 2003 | 183 | 0.180 |
Why?
| | Pleurotus | 1 | 2021 | 1 | 0.180 |
Why?
| | Pregnancy | 4 | 2020 | 7039 | 0.170 |
Why?
| | src-Family Kinases | 4 | 2012 | 94 | 0.170 |
Why?
| | Nitric Oxide | 2 | 2016 | 898 | 0.170 |
Why?
| | Phosphorylation | 5 | 2021 | 1760 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2016 | 528 | 0.160 |
Why?
| | Interleukin-33 | 2 | 2017 | 50 | 0.160 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2020 | 12 | 0.160 |
Why?
| | Receptors, Prostaglandin | 1 | 2020 | 22 | 0.160 |
Why?
| | Enzyme Activation | 6 | 2012 | 801 | 0.160 |
Why?
| | Protein Transport | 2 | 2013 | 448 | 0.160 |
Why?
| | Carrier Proteins | 1 | 2004 | 746 | 0.160 |
Why?
| | Protein Binding | 7 | 2016 | 2243 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 3 | 2010 | 183 | 0.150 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 2 | 2016 | 45 | 0.150 |
Why?
| | Immunologic Memory | 1 | 2021 | 359 | 0.150 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2016 | 44 | 0.150 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 244 | 0.150 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 215 | 0.140 |
Why?
| | DNA | 1 | 2025 | 1441 | 0.140 |
Why?
| | Female | 17 | 2025 | 75728 | 0.140 |
Why?
| | Interleukin-9 | 1 | 2017 | 13 | 0.140 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 25 | 0.140 |
Why?
| | Macrophages | 1 | 2025 | 1563 | 0.130 |
Why?
| | Immunization | 2 | 2018 | 405 | 0.130 |
Why?
| | Virulence Factors | 2 | 2016 | 162 | 0.130 |
Why?
| | Adoptive Transfer | 3 | 2021 | 223 | 0.130 |
Why?
| | Enzyme Inhibitors | 3 | 2015 | 843 | 0.130 |
Why?
| | Lymphocyte Subsets | 1 | 2017 | 88 | 0.130 |
Why?
| | Endocytosis | 2 | 2009 | 173 | 0.130 |
Why?
| | Yersinia | 1 | 2016 | 2 | 0.130 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2016 | 17 | 0.130 |
Why?
| | Enzyme Induction | 2 | 2014 | 90 | 0.130 |
Why?
| | Toluidines | 1 | 2016 | 10 | 0.130 |
Why?
| | Rosaniline Dyes | 1 | 2016 | 15 | 0.130 |
Why?
| | Benzenesulfonates | 1 | 2016 | 23 | 0.130 |
Why?
| | Acetylation | 2 | 2016 | 245 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 149 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 661 | 0.120 |
Why?
| | Caffeic Acids | 1 | 2016 | 2 | 0.120 |
Why?
| | Yersinia enterocolitica | 1 | 2016 | 7 | 0.120 |
Why?
| | Succinates | 1 | 2016 | 23 | 0.120 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2016 | 74 | 0.120 |
Why?
| | Microtubule Proteins | 2 | 2007 | 16 | 0.120 |
Why?
| | Tubulin Modulators | 1 | 2015 | 10 | 0.120 |
Why?
| | Ferrous Compounds | 1 | 2015 | 24 | 0.120 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 97 | 0.120 |
Why?
| | Cell Culture Techniques | 2 | 2016 | 368 | 0.120 |
Why?
| | Tumor Suppressor p53-Binding Protein 1 | 1 | 2015 | 13 | 0.120 |
Why?
| | Peroxides | 1 | 2015 | 19 | 0.120 |
Why?
| | Reactive Nitrogen Species | 1 | 2015 | 19 | 0.120 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2015 | 24 | 0.120 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 145 | 0.120 |
Why?
| | Calcifediol | 1 | 2015 | 32 | 0.120 |
Why?
| | Drug Synergism | 1 | 2016 | 370 | 0.110 |
Why?
| | Active Transport, Cell Nucleus | 2 | 2012 | 123 | 0.110 |
Why?
| | Antibodies, Blocking | 1 | 2015 | 36 | 0.110 |
Why?
| | Lipid Peroxidation | 1 | 2015 | 150 | 0.110 |
Why?
| | Cytokinesis | 1 | 2015 | 50 | 0.110 |
Why?
| | Estrogen Receptor alpha | 1 | 2016 | 145 | 0.110 |
Why?
| | Mucus | 2 | 2017 | 78 | 0.110 |
Why?
| | Doxorubicin | 1 | 2016 | 370 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 2 | 2012 | 273 | 0.110 |
Why?
| | Cellular Senescence | 1 | 2016 | 206 | 0.110 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2016 | 214 | 0.110 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 281 | 0.110 |
Why?
| | Histones | 2 | 2016 | 639 | 0.100 |
Why?
| | Growth Inhibitors | 2 | 2012 | 45 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2009 | 374 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 181 | 0.100 |
Why?
| | Interleukin-4 | 2 | 2014 | 215 | 0.100 |
Why?
| | Lung | 2 | 2022 | 4129 | 0.100 |
Why?
| | Molecular Dynamics Simulation | 4 | 2016 | 247 | 0.100 |
Why?
| | Alternaria | 2 | 2025 | 11 | 0.100 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2013 | 57 | 0.100 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 676 | 0.100 |
Why?
| | Swine | 1 | 2016 | 810 | 0.100 |
Why?
| | Myristic Acids | 1 | 2012 | 8 | 0.100 |
Why?
| | Interleukins | 1 | 2015 | 250 | 0.100 |
Why?
| | Myristic Acid | 1 | 2012 | 10 | 0.100 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2012 | 15 | 0.100 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2012 | 14 | 0.100 |
Why?
| | Carcinogenesis | 1 | 2015 | 218 | 0.100 |
Why?
| | Retinal Dystrophies | 1 | 2012 | 5 | 0.100 |
Why?
| | Pre-Eclampsia | 1 | 2015 | 200 | 0.100 |
Why?
| | DNA Damage | 1 | 2015 | 430 | 0.100 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2012 | 23 | 0.100 |
Why?
| | Novobiocin | 1 | 2012 | 5 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2012 | 44 | 0.090 |
Why?
| | Biomarkers | 3 | 2020 | 4179 | 0.090 |
Why?
| | Macrolides | 1 | 2012 | 69 | 0.090 |
Why?
| | Pyrrolidinones | 1 | 2011 | 30 | 0.090 |
Why?
| | Models, Biological | 2 | 2012 | 1826 | 0.090 |
Why?
| | Tissue Engineering | 1 | 2016 | 429 | 0.090 |
Why?
| | Endosomes | 2 | 2010 | 144 | 0.090 |
Why?
| | Culture Media | 1 | 2011 | 163 | 0.090 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2012 | 130 | 0.090 |
Why?
| | Triazoles | 1 | 2012 | 163 | 0.080 |
Why?
| | Age of Onset | 1 | 2012 | 534 | 0.080 |
Why?
| | Enzyme Stability | 1 | 2010 | 71 | 0.080 |
Why?
| | Biosensing Techniques | 1 | 2011 | 138 | 0.080 |
Why?
| | Actins | 2 | 2009 | 423 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 1440 | 0.080 |
Why?
| | Dynamins | 1 | 2009 | 38 | 0.080 |
Why?
| | Ambrosia | 1 | 2009 | 7 | 0.080 |
Why?
| | Eosinophils | 2 | 2012 | 325 | 0.080 |
Why?
| | Aspergillus | 1 | 2009 | 19 | 0.080 |
Why?
| | Th1 Cells | 1 | 2010 | 139 | 0.080 |
Why?
| | Pyroglyphidae | 1 | 2009 | 19 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 1769 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1232 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 451 | 0.070 |
Why?
| | Myosins | 1 | 2009 | 137 | 0.070 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 628 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 306 | 0.070 |
Why?
| | Indoles | 1 | 2012 | 475 | 0.070 |
Why?
| | Arthritis, Experimental | 1 | 2010 | 141 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2016 | 1114 | 0.070 |
Why?
| | eIF-2 Kinase | 1 | 2008 | 31 | 0.070 |
Why?
| | Antigen Presentation | 1 | 2009 | 219 | 0.070 |
Why?
| | Cytoskeleton | 1 | 2009 | 194 | 0.070 |
Why?
| | Multiprotein Complexes | 1 | 2009 | 171 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-fyn | 1 | 2007 | 12 | 0.070 |
Why?
| | GATA3 Transcription Factor | 2 | 2020 | 24 | 0.070 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 14 | 0.070 |
Why?
| | Transfection | 2 | 2007 | 936 | 0.070 |
Why?
| | Umbilical Veins | 1 | 2007 | 61 | 0.070 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2007 | 145 | 0.060 |
Why?
| | Eye Proteins | 1 | 2007 | 92 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2010 | 517 | 0.060 |
Why?
| | Mitochondria | 1 | 2013 | 975 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1369 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2008 | 315 | 0.060 |
Why?
| | Feedback | 1 | 2007 | 178 | 0.060 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2006 | 22 | 0.060 |
Why?
| | Bronchi | 1 | 2008 | 267 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2026 | 1244 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2006 | 142 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 2004 | 533 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2008 | 335 | 0.060 |
Why?
| | Adult | 7 | 2021 | 39203 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 174 | 0.060 |
Why?
| | Methylation | 1 | 2026 | 231 | 0.060 |
Why?
| | Neurons | 1 | 2014 | 1615 | 0.060 |
Why?
| | Tyrosine | 1 | 2006 | 229 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 329 | 0.060 |
Why?
| | Down-Regulation | 2 | 2021 | 639 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2010 | 2178 | 0.050 |
Why?
| | Molecular Structure | 2 | 2016 | 501 | 0.050 |
Why?
| | Cell Line | 3 | 2016 | 2880 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1052 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2014 | 1196 | 0.050 |
Why?
| | src Homology Domains | 1 | 2004 | 36 | 0.050 |
Why?
| | Rats | 2 | 2010 | 5595 | 0.050 |
Why?
| | Nerve Tissue Proteins | 2 | 2009 | 605 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2555 | 0.050 |
Why?
| | Middle Aged | 7 | 2021 | 34597 | 0.050 |
Why?
| | Helminth Proteins | 1 | 2002 | 26 | 0.050 |
Why?
| | Antigen-Presenting Cells | 1 | 2003 | 159 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 1019 | 0.050 |
Why?
| | Kinetics | 2 | 2015 | 1654 | 0.040 |
Why?
| | Mutation | 1 | 2012 | 4009 | 0.040 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2905 | 0.040 |
Why?
| | DNA Methylation | 1 | 2026 | 641 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 950 | 0.040 |
Why?
| | Phytotherapy | 1 | 2021 | 82 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2021 | 77 | 0.040 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2002 | 214 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2020 | 166 | 0.040 |
Why?
| | NIH 3T3 Cells | 2 | 2009 | 149 | 0.040 |
Why?
| | Chemokines | 2 | 2009 | 228 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2003 | 858 | 0.030 |
Why?
| | Respiratory Hypersensitivity | 1 | 2017 | 68 | 0.030 |
Why?
| | Chaperonins | 1 | 2016 | 6 | 0.030 |
Why?
| | Serum Amyloid A Protein | 1 | 2016 | 33 | 0.030 |
Why?
| | RNA | 1 | 2003 | 930 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 567 | 0.030 |
Why?
| | Complement C3a | 1 | 2016 | 42 | 0.030 |
Why?
| | Young Adult | 2 | 2010 | 13667 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 107 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 123 | 0.030 |
Why?
| | Chlorogenic Acid | 1 | 2016 | 3 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 163 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1812 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 173 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2016 | 328 | 0.030 |
Why?
| | Breeding | 1 | 2016 | 65 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 327 | 0.030 |
Why?
| | Child | 1 | 2016 | 22341 | 0.030 |
Why?
| | Peracetic Acid | 1 | 2015 | 5 | 0.030 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 2015 | 9 | 0.030 |
Why?
| | Cell Extracts | 1 | 2015 | 21 | 0.030 |
Why?
| | Enzyme Assays | 1 | 2015 | 25 | 0.030 |
Why?
| | Aged | 3 | 2010 | 24798 | 0.030 |
Why?
| | Yersinia pestis | 1 | 2015 | 45 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2015 | 126 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 147 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2017 | 560 | 0.030 |
Why?
| | Male | 6 | 2025 | 70062 | 0.030 |
Why?
| | Phenotype | 1 | 2003 | 3177 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2015 | 81 | 0.030 |
Why?
| | Plague | 1 | 2015 | 60 | 0.030 |
Why?
| | Cysteine | 1 | 2016 | 208 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 136 | 0.030 |
Why?
| | Airway Remodeling | 1 | 2015 | 69 | 0.030 |
Why?
| | Virulence | 1 | 2015 | 268 | 0.030 |
Why?
| | Drug Interactions | 1 | 2015 | 404 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 295 | 0.030 |
Why?
| | Bronchoscopy | 1 | 2014 | 225 | 0.020 |
Why?
| | Adolescent | 2 | 2010 | 22064 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 861 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2016 | 888 | 0.020 |
Why?
| | Carboxylic Acids | 1 | 2012 | 33 | 0.020 |
Why?
| | Binding Sites | 1 | 2016 | 1315 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2012 | 191 | 0.020 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2011 | 19 | 0.020 |
Why?
| | Dexamethasone | 1 | 2014 | 379 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 198 | 0.020 |
Why?
| | Stereoisomerism | 1 | 2011 | 104 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1087 | 0.020 |
Why?
| | Models, Molecular | 1 | 2016 | 1603 | 0.020 |
Why?
| | Clonal Anergy | 1 | 2010 | 52 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2014 | 533 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 117 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 386 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 317 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3580 | 0.020 |
Why?
| | GTP Phosphohydrolases | 1 | 2009 | 94 | 0.020 |
Why?
| | Placenta | 1 | 2015 | 764 | 0.020 |
Why?
| | Chemokine CCL11 | 1 | 2008 | 27 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 855 | 0.020 |
Why?
| | Autocrine Communication | 1 | 2008 | 40 | 0.020 |
Why?
| | Bacteria | 1 | 2015 | 875 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2008 | 187 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 159 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1764 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2798 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2008 | 327 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 50 | 0.020 |
Why?
| | Bronchial Provocation Tests | 1 | 2006 | 50 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2006 | 111 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2009 | 502 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1492 | 0.010 |
Why?
| | Blood Vessels | 1 | 2006 | 180 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 856 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 399 | 0.010 |
Why?
| | Receptors, Interleukin-5 | 1 | 2002 | 6 | 0.010 |
Why?
| | Receptors, Interleukin | 1 | 2002 | 45 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 918 | 0.010 |
Why?
| | DNA Primers | 1 | 2002 | 508 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1672 | 0.010 |
Why?
| | Prevalence | 1 | 2006 | 2793 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2172 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2153 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2919 | 0.010 |
Why?
|
|
Gorska's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|